Verona Pharma PLC - ESG Rating & Company Profile powered by AI
The page includes a Q&A table for Verona Pharma PLC. Alternative corporations in the rating peer group for Verona Pharma PLC are shown below. The ESG rating includes 17 United Nations Sustainable Development Goals including: 'Clean Water & Sanitation', 'Sustainable Cities & Communities' and 'Life on Land'.
Verona Pharma PLC in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 2.1; made up of an environmental score of 1.6, social score of 1.6 and governance score of 2.7.
2.1
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| ... | ... | ... | |
| 2095 | Qurient Co Ltd | 2.2 | Medium |
| 2095 | Resonate Blends Inc | 2.2 | Medium |
| 2110 | Verona Pharma PLC | 2.1 | Medium |
| 2110 | BTG Management Services Ltd | 2.1 | Medium |
| 2110 | Aurisco Pharmaceutical Co Ltd | 2.1 | Medium |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Verona Pharma PLC have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Verona Pharma PLC disclose current and historical energy intensity?
Sign up for free to unlockDoes Verona Pharma PLC report the average age of the workforce?
Sign up for free to unlockDoes Verona Pharma PLC reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Verona Pharma PLC disclose its ethnicity pay gap?
Sign up for free to unlockDoes Verona Pharma PLC disclose cybersecurity risks?
Sign up for free to unlockDoes Verona Pharma PLC offer flexible work?
Sign up for free to unlockDoes Verona Pharma PLC have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Verona Pharma PLC disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Verona Pharma PLC conduct supply chain audits?
Sign up for free to unlockDoes Verona Pharma PLC disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Verona Pharma PLC conduct 360 degree staff reviews?
Sign up for free to unlockDoes Verona Pharma PLC disclose the individual responsible for D&I?
Sign up for free to unlockDoes Verona Pharma PLC disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Verona Pharma PLC disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Verona Pharma PLC disclose water use targets?
Sign up for free to unlockDoes Verona Pharma PLC have careers partnerships with academic institutions?
Sign up for free to unlockDid Verona Pharma PLC have a product recall in the last two years?
Sign up for free to unlockDoes Verona Pharma PLC disclose incidents of discrimination?
Sign up for free to unlockDoes Verona Pharma PLC allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Verona Pharma PLC issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Verona Pharma PLC disclose parental leave metrics?
Sign up for free to unlockDoes Verona Pharma PLC disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Verona Pharma PLC disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Verona Pharma PLC disclose the pay ratio of women to men?
Sign up for free to unlockDoes Verona Pharma PLC support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Verona Pharma PLC disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Verona Pharma PLC reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Verona Pharma PLC involved in embryonic stem cell research?
Sign up for free to unlockDoes Verona Pharma PLC disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Verona Pharma PLC disclose its waste policy?
Sign up for free to unlockDoes Verona Pharma PLC report according to TCFD requirements?
Sign up for free to unlockDoes Verona Pharma PLC disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Verona Pharma PLC disclose energy use targets?
Sign up for free to unlockDoes Verona Pharma PLC disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Verona Pharma PLC have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Verona Pharma PLC
These potential risks are based on the size, segment and geographies of the company.
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.